Cranberry Extract (PAC-A)

📜 Historical Use

Cranberry is an evergreen shrub that grows in wet habitats across the northeastern and north central parts of North America. The plants behind the supplements are Vaccinium macrocarpon, also known as Oxycoccus macrocarpos, and Vaccinium oxycoccos; common names include cranberry, American cranberry and bearberry. It has a long record of traditional use in dyes, food and medicine among Native Americans and, later, European settlers, and the traditional indications were considerably broader than the modern one. Cranberry fruits and leaves were thought to have therapeutic effects on disorders of the bladder, stomach, blood and liver, and on conditions as varied as wounds, diabetes and scurvy. Only the bladder use has carried through to the present. Today cranberry is promoted mainly for urinary tract infections and recurrent UTIs, and NCCIH is explicit about part of why it is having a moment: interest in nonantibiotic prevention strategies has grown because of concerns about antibiotic-resistant bacteria. That framing is worth keeping in view when reading the evidence, because it explains why a supplement with inconsistent trial results attracts such sustained attention - the appeal is partly the problem it might let people avoid, not only the benefit it has been shown to deliver.

📊 What the Research Shows

Cranberry has been studied a great deal for UTI prevention, particularly in women at increased risk of recurrent infection, but NCCIH notes plainly that some of that research is not of high quality. The headline finding is that cranberry products may decrease the overall risk of symptomatic, recurrent UTIs in women by 25 percent, and in some cases by more than 30 percent. NCCIH then qualifies its own headline: the effectiveness of cranberry is still in question because of inconsistent findings. Both halves of that belong on any honest page. The more useful detail is where the effect does not appear. Studies in populations at increased risk of UTI - elderly people in long-term care, and pregnant women - have had inconsistent results. Studies in other high-risk groups, specifically women undergoing gynecological surgeries and people with multiple sclerosis, have not found cranberry to reduce UTI risk at all. So the groups with the most to gain are the groups where the evidence is weakest or negative. NCCIH is also unambiguous that cranberry is not recommended as a treatment for an existing UTI in any population. Regulators have landed in the same place: since 2020 the FDA has permitted manufacturers to say there is "limited" evidence that daily consumption of specified amounts of cranberry supplements may reduce recurrent UTI risk in healthy women, and for juice beverages the evidence must be described as "limited and inconsistent". Outside UTIs, NCCIH reports there is little research on cranberry for any condition.

Take 36mg PAC-A standardized extract daily. Or drink 8oz unsweetened cranberry juice 2x daily.

Use unsweetened products only. May interact with warfarin. Not for treating active infections alone.

⚠️ What happens if taken in excess:

Generally safe. Very high doses of cranberry supplements may increase kidney stone risk (oxalate stones). Can enhance warfarin effects, increasing bleeding risk. Excessive cranberry juice consumption (unsweetened) may cause GI upset. Sweetened cranberry drinks provide excess sugar.

One drug is named, and the finding about it is uncertainty rather than a warning. NCCIH states that there is conflicting evidence about whether cranberry interacts with the anticoagulant warfarin. Conflicting is the operative word: the fact sheet asserts neither a direction nor a magnitude, so a page telling you that cranberry enhances warfarin and raises bleeding risk is stating as settled something the federal source explicitly describes as unresolved. For anyone on warfarin the practical implication is unchanged - tell the prescriber and let INR monitoring answer the question - but the page should not manufacture certainty. What is absent is also informative. The NCCIH cranberry fact sheet names no cytochrome P450 enzyme, no transporter such as P-glycoprotein, and no second interacting drug. That is a meaningfully different profile from herbs where NCCIH does have evidence to give: for St. John's wort, for instance, it describes potent induction of cytochrome P-450 enzymes and intestinal P-glycoprotein with documented interactions involving cyclosporine, indinavir, oral contraceptives, warfarin and digoxin. No comparable catalogue exists for cranberry. Absence of a documented interaction is not proof of safety, though, and NCCIH's standing instruction applies: if you take warfarin or any other medicine, talk with your health care provider before using cranberry, because some herbs and medicines interact in harmful ways.

1. Cranberry: Usefulness and Safety — National Center for Complementary and Integrative Health NCCIH Herbs at a Glance, National Institutes of Health (2024)[NIH ↗]